Clinical Evaluation of Human Papillomavirus Detection by careHPVTM Test on Physician-Samples and Self-Samples using The Indicating FTA Elute® Card

  • Wang, Shao-Ming ;
  • Hu, Shang-Ying ;
  • Chen, Feng ;
  • Chen, Wen ;
  • Zhao, Fang-Hui ;
  • Zhang, Yu-Qing ;
  • Ma, Xin-Ming ;
  • Qiao, You-Lin
  • Published : 2014.09.15


Objective: To make the clinical evaluation of a solid-state human papillomavirus (HPV) sampling medium in combination with an economical HPV testing method ($careHPV^{TM}$) for cervical cancer screening. Methods: 396 women aged 25-65 years were enrolled for cervical cancer screening, and four samples were collected. Two samples were collected by woman themselves, among which one was stored in DCM preservative solution (called "liquid sample") and the other was applied on the Whatman Indicating FTA $Elute^{(R)}$ card (FTA card). Another two samples were collected by physician and stored in DCM preservative solution and FTA card, respectively. All the samples were detected by $careHPV^{TM}$ test. All the women were administered a colposcopy examination, and biopsies were taken for pathological confirmation if necessary. Results: FTA card demonstrated a comparable sensitivity of detecting high grade Cervical Intraepithelial Neoplasia (CIN) with the liquid sample carrier for self and physician-sampling, but showed a higher specificity than that of liquid sample carrier for self-sampling (FTA vs Liquid: 79.0% vs 71.6%, p=0.02). Generally, the FTA card had a comparable accuracy with that of Liquid-based medium by different sampling operators, with an area under the curve of 0.807 for physician &FTA, 0.781 for physician &Liquid, 0.728 for self & FTA, and 0.733 for self &Liquid (p>0.05). Conclusions: FTA card is a promising sample carrier for cervical cancer screening. With appropriate education programmes and further optimization of the experimental workflow, FTA card based self-collection in combination with centralized $careHPV^{TM}$ testing can help expand the coverage of cervical cancer screening in low-resource areas.


Whatman Indicating FTA $Elute^{(R)}$ card;cervical cancer screening;self-sampling;$careHPV^{TM}$ test


  1. Arbyn M, Ronco G, Anttila A, et al (2012). Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine, 30, 88-99.
  2. Gage JC, Ajenifuja KO, Wentzensen N, et al (2012). Effectiveness of a simple rapid human papillomavirus DNA test in rural Nigeria. Int J Cancer, 131, 2903-9.
  3. Gonzalez P, Cortes B, Quint W, et al (2012). Evaluation of the FTA carrier device for human papillomavirus testing in developing countries. J Clin Microbiol, 50, 3870-6.
  4. Guan Y, Castle PE, Wang S, et al (2012). A cross-sectional study on the acceptability of self-collection for HPV testing among women in rural China. Sex Transm Infect, 88, 490-4.
  5. Guan Y, Gravitt PE, Howard R, et al (2013). Agreement for HPV genotyping detection between self-collected specimens on a FTA cartridge and clinician-collected specimens. J Virol Methods, 189, 167-71.
  6. Gustavsson I, Lindell M, Wilander E, et al (2009). Use of FTA card for dry collection, transportation and storage of cervical cell specimen to detect high-risk HPV. J Clin Virol, 46, 112-6.
  7. Gustavsson I, Sanner K, Lindell M, et al (2011). Type-specific detection of high-risk human papillomavirus (HPV) in selfsampled cervicovaginal cells applied to FTA elute cartridge. J Clin Virol, 51, 255-8.
  8. IARC (2005). Cervix Cancer Screening IARC Handbooks of Cancer Prevention 10.
  9. Kang LN, Jeronimo J, Qiao YL, et al (2014). Optimal positive cutoff points for careHPV testing of clinician- and selfcollected specimens in primary cervical cancer screening: an analysis from rural China. J Clin Microbiol, 52, 1954-61.
  10. Lenselink CH, de Bie RP, van Hamont D, et al (2009). Detection and genotyping of human papillomavirus in self-obtained cervicovaginal samples by using the FTA cartridge: new possibilities for cervical cancer screening. J Clin Microbiol, 47, 2564-70.
  11. Phongsavan K, Gustavsson I, Marions L, et al (2012). Detection of human papillomavirus among women in Laos: feasibility of using filter paper card and prevalence of high-risk types. Int J Gynecol Cancer, 22, 1398-406.
  12. Qiao YL, Sellors JW, Eder PS, et al (2008). A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol, 9, 929-36.
  13. Ronco G, Dillner J, Elfstrom KM, et al (2014). Efficacy of HPVbased screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet, 383, 524-32.
  14. Sankaranarayanan R, Esmy PO, Rajkumar R, et al (2007). Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet, 370, 398-406.
  15. Yoshida T, Nishijima Y, Hando K, et al (2013). Primary study on providing a basic system for uterine cervical screening in a developing country: analysis of acceptability of selfsampling in Lao PDR. Asian Pac J Cancer Prev, 14, 3029-35.
  16. Zhang SK, Ci PW, Velicer C, et al (2014). Comparison of HPV genotypes and viral load between different sites of genital tract: the significance for cervical cancer screening. Cancer Epidemiol, 38, 168-73.
  17. Zhao FH, Lin MJ, Chen F, et al (2010). Performance of highrisk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol, 11, 1160-71.

Cited by

  1. An Evaluation of the Cobas4800 HPV Test on Cervico-Vaginal Specimens in Liquid versus Solid Transport Media vol.11, pp.2, 2016,
  2. Protein Detection Using the Multiplexed Proximity Extension Assay (PEA) from Plasma and Vaginal Fluid Applied to the Indicating FTA Elute Micro Card™ vol.5, pp.1849-4544, 2016,
  3. Vaginal self-sampling as a diagnosis tool in low-income countries and potential applications for exploring the infectious causes of miscarriage vol.12, pp.7, 2017,
  4. Advances in paper-based sample pretreatment for point-of-care testing vol.37, pp.4, 2017,
  5. Integrated paper-based microfluidic devices for point-of-care testing vol.10, pp.29, 2018,